CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions: Endorsed by the Chinese Society of Cardiology Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association In-stent neoatherosclerosis: a final common pathway of late stent failure Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial

GuidelineVolume 73, Issue 24, June 2019

JOURNAL:J Am Coll Cardiol. Article Link

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

SM Grundy, NJ Stone, AL Bailey et al. Keywords: ACC/AHA Clinical Practice Guidelines; biomarkers; coronary artery calcium score; pharmacological; cardiovascular disease; cholesterol; LDL-cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention; ezetimibe; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors

FULL TEXT PDF